Environmental designer drugs: when transformation may not eliminate risk. [PDF]
Environ Sci Technol, 2014 Cwiertny DM +3 more
europepmc +1 more source
Metabolism of α-PHP and α-PHPP in humans and the effects of alkyl chain lengths on the metabolism of α-pyrrolidinophenone-type designer drugs. [PDF]
Forensic Toxicol, 2018 Matsuta S +11 more
europepmc +1 more source
Baths salts, spice, and related designer drugs: the science behind the headlines. [PDF]
J Neurosci, 2014 Baumann MH +5 more
europepmc +1 more source
Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs. [PDF]
J Neurosci, 2016 Burnett CJ, Krashes MJ.
europepmc +1 more source
Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays. [PDF]
J Cheminform, 2014 Krasowski MD, Ekins S.
europepmc +1 more source
The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs. [PDF]
ACS Chem Neurosci, 2015 Chen X +6 more
europepmc +1 more source
Educated Guesses and Other Ways to Address the Pharmacological Uncertainty of Designer Drugs: An Exploratory Study of Experimentation Through an Online Drug Forum. [PDF]
Contemp Drug Probl, 2016 Berning M, Hardon A.
europepmc +1 more source
'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting. [PDF]
Clin Med (Lond), 2014 Smith CD, Robert S.
europepmc +1 more source
Directed biosynthesis of the designer peptidyl nucleoside antibiotics featuring a simplified azetidine-containing moiety. [PDF]
Synth Syst BiotechnolGong R +11 more
europepmc +1 more source